



Press Release

Monday, October 4, 2010

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

STRIDES ARCOLAB RECORDS 50TH ANDA APPROVAL 2 More ANDA Approvals Received

Strides Arcolab Limited (Strides) today announced that it has received its 50th USFDA ANDA approval with approvals for the following two products:



- Lidocaine Hydrochloride Injection USP, 20 mg/mL (preservative-free), packaged in 100 mgs/5 mL single-use vials
- Lidocaine Hydrochloride Injection USP, 0.5% (5mg/mL) & 1% (10mg/mL), packaged in single-use vials.

Of the 50 approvals received to date, 31 are for Sterile products, a segment in which Strides has established itself as a leading player worldwide. In 2010, the Company received 19 approvals, of which 14 are in the Steriles space.

According to IMS data, the total US market for Lidocaine injection in 2009 approximated US\$ 61 million. Half of this market will be covered by the two products for which approvals have been received. The products are expected to be launched in the near future. Strides has also filed applications for the balance strengths, approvals for which are awaited.

About Lidocaine Hydrochloride Injection

Lidocaine Hydrochloride Injection antiarrhythmic agent (used to treat irregular heartbeat) is administered intravenously by direct injection. The drug may also be used for resistant seizure treatment. Studies of the effects of therapeutic concentrations of Lidocaine on the electrophysiological properties of mammalian Purkinje fibres have shown that Lidocaine attenuates phase 4 diastolic depolarization, decreases automaticity, and causes a decrease or no change in excitability and membrane responsiveness.



It is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. Lidocaine Hydrochloride should not be used in patients with Stokes-Adams syndrome, Wolff-Parkinson-White syndrome, or with severe degrees of sinoatrial, atrioventricular or intraventricular block in the absence of an artificial pacemaker.

About Strides Arcolab Limited:

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

V S Iyer CEO – India Operations Ph: +91 80 6658 0111	Mr. Mahesh Nair, Corporate Voice Weber Shandwick Mobile : +91 98803 76648 Email: maheshn@corvoshandwick.co.in
Mr. N Kannan (Investor Relations) Tel : +91 98450 54745	Ms. Kasturi Wasmatar, Corporate Voice Weber Shandwick Mobile: +91 99167 28393 Email: kasturi@corvoshandwick.co.in
Ms. Melissa Arulappan (Media) Tel: +91 98450 22389	

